Patents by Inventor Martin Dreyling

Martin Dreyling has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SUBCUTANEOUSLY ADMINISTERED BISPECIFIC ANTIBODIES FOR USE IN THE TREATMENT OF CANCER
    Publication number: 20170224818
    Abstract: The present invention relates to the use of T cell redirecting, bispecific, in particular trifunctional, antibodies for the treatment of a cancer disease, wherein said antibody is administered via the subcutaneous route. Thereby, the release of proinflammatory cytokines is reduced and, simultaneously, the release of inhibitory cytokines is substantially suppressed. That treatment by bispecific, in particular trifunctional, antibodies may be combined in a combination therapy with other anti-cancer drugs.
    Type: Application
    Filed: August 10, 2015
    Publication date: August 10, 2017
    Inventors: Horst LINDHOFER, Raymund BUHMANN, Martin DREYLING, Wolfgang HIDDEMANN
  • COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH FLUDARABINE AND/OR MITOXANTRONE
    Publication number: 20150274834
    Abstract: The present invention is directed to the combination therapy of an afucosylated anti-CD20 antibody with fludarabine and/or mitoxantrone for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with an afucosylated humanized B-Ly1 antibody with fludarabine and/or mitoxantrone.
    Type: Application
    Filed: June 15, 2015
    Publication date: October 1, 2015
    Applicant: ROCHE GLYCART AG
    Inventors: Martin Dreyling, Daniel Alexander Heinrich, Frank Herting, Christian Klein
  • COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH FLUDARABINE AND/OR MITOXANTRONE
    Publication number: 20150079073
    Abstract: The present invention is directed to the combination therapy of an afucosylated anti-CD20 antibody with fludarabine and/or mitoxantrone for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with an afucosylated humanized B-Ly1 antibody with fludarabine and/or mitoxantrone.
    Type: Application
    Filed: April 11, 2014
    Publication date: March 19, 2015
    Applicant: Roche Glycart AG
    Inventors: MARTIN DREYLING, DANIEL ALEXANDER HEINRICH, FRANK HERTING, CHRISTIAN KLEIN
  • Combination therapy of an afucosylated CD20 antibody with fludarabine and/or mitoxantrone
    Publication number: 20120263713
    Abstract: The present invention is directed to the combination therapy of an afucosylated anti-CD20 antibody with fludarabine and/or mitoxantrone for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with an afucosylated humanized B-Ly1 antibody with fludarabine and/or mitoxantrone.
    Type: Application
    Filed: June 6, 2012
    Publication date: October 18, 2012
    Inventors: Martin Dreyling, Daniel Alexander Heinrich, Frank Herting, Christian Klein
  • COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH FLUDARABINE AND/OR MITOXANTRONE
    Publication number: 20110165152
    Abstract: The present invention is directed to the combination therapy of an afucosylated anti-CD20 antibody with fludarabine and/or mitoxantrone for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with an afucosylated humanized B-Ly1 antibody with fludarabine and/or mitoxantrone.
    Type: Application
    Filed: August 13, 2010
    Publication date: July 7, 2011
    Inventors: Martin Dreyling, Daniel Alexander Heinrich, Frank Herting, Christian Klein